Skip to main content

Bipolar Disorder: Assessment for diabetes

New or Maintenance
Endorsement and Maintenance (E&M) Cycle
Measure Description

Percentage of patients treated for bipolar disorder who are assessed for diabetes within 16 weeks after initiating treatment with an atypical antipsychotic agent.

  • Numerator

    Assessment for diabetes must include documentation of one of the following:
    • Reference in chart that test was ordered and results or information about results was obtained
    • Lab results filed in chart or available in patient’s electronic medical record
    Reference: Tests used to screen/assess for diabetes:
    Preferred Fasting plasma glucose; Non-fasting plasma glucose; Glucose tolerance Also Accepted: Glycosylated hemoglobin (Hb A1c; glycated hemoglobin) Random glucose AND

    Timeframe: Test results/information from test conducted within 16 weeks after the initiation of a second generation atypical antipsychotic agent
    Numerator criteria not applicable and exclusion from compliance as stated below:
    1.Dcumentation by physician that test was not clinically indicated for this patient
    2Documentation that test was requested but patient failed to comply with request to obtain test


    Patients 18 years of age or older with an initial or new episode of bipolar disorder
    Documentation of a diagnosis of bipolar disorder; to include at least one of the following:
    • Codes 296.0x; 296.1x; 296.4x; 296.5x; 296.6x; 296.7; 296.80; 296.81; 296.82; 296.89; 301.13 documented in body of chart, such as a pre-printed form completed by a clinician and/or codes documented in chart notes/forms
    • Diagnosis or Impression or “working diagnosis” documented in chart indicating bipolar disorder
    • Use of a screening/assessment tool for bipolar disorder with a score or conclusion that patient has bipolar disorder and documentation that this information is used to establish or substantiate the diagnosis
    Documentation of treatment with an atypical antipsychotic agent. (See reference list below)
    Note: It is not the intent to indicate preferred pharmacotherapy. The reference list is inclusive of those atypical antipsychotic medications that are reasonably construed to be appropriate in accordance with current guidelines. (Reference list of medications also included in data collection form)
    Atypical Antipsychotic Agents
    • aripiprazole
    • quetiapine
    • clozapine
    • risperidone
    • olanzapine
    • ziprasidone
    • olanzapine-fluoxetine (combination)

    None. New diagnosis” or a “new episode,” is defined as cases where the patient has not been involved in active treatment for 6 months. Active treatment includes being hospitalized or under the out-patient care of a physician.



    Select the data sources for which you have tested and specified the measure.
  • Most Recent Endorsement Activity
    Measure Retired and Endorsement Removed Behavioral Health Project 2013-2015
    Initial Endorsement
    Cycle Division
    Cycle Year
    Endorsement Status
    Last Updated
    Removal Date